UnitedHealthcare GI Pathogen Panel Coverage Update

Coverage Criteria for Gastrointestinal Pathogen Panels

Proven and medically necessary — up to 5-target multiplex PCR

Covered when ALL of the following are met:

Panel up to 5 targets: Multiplex PCR panel testing including up to 5 targets is medically necessary when performed as part of an evaluation that includes blood cultures for an individual with ANY one of: diarrhea for more than 7 days; OR diarrhea with at least one of fever, bloody or mucoid stools, severe abdominal cramping or tenderness, signs of sepsis; OR suspected enteric fever in a person with recent travel to an endemic region or exposure to foods prepared by persons with recent endemic exposure.

Proven and medically necessary — up to 11-target multiplex PCR for persistent diarrhea / immunosuppressed

Covered when ALL of the following are met:

Panel up to 11 targets: Multiplex PCR panel testing including up to 11 targets is medically necessary for evaluation of persistent diarrhea in an individual with ANY one of: at risk for Clostridium difficile colitis and one of: diarrhea for more than 7 days OR diarrhea with at least one of fever, bloody or mucoid stools, severe abdominal cramping or tenderness, signs of sepsis; OR other conditions causing immunosuppression when other stool diagnostic studies have failed to yield a pathogenic organism.

Unproven and not medically necessary

Not medically necessary conditions: Multiplex PCR panel testing for gastrointestinal pathogens for all other indications; and multiplex PCR panels with more than 11 targets are unproven and not medically necessary.

Covered use criteria (clinical indication, stewardship/IPC impact, culture reflex when isolates required)

Covered when ALL of the following are met

Clinical indication: Patient meets clinical testing criteria consistent with IDSA (e.g., fever, abdominal pain, bloody stool) or is immunocompromised, or other documented justification such as severe disease or symptoms >7 days or need to guide infection control; documentation should be present in the medical record.

Applying IDSA criteria reduced testing by ~32% without reducing clinical yield (Clark et al.).

Use cases favoring panels: Rapid turnaround is expected to change management (for example, to inform antibiotic therapy, isolation decisions, or inpatient antimicrobial stewardship).

Studies report faster reporting times and associated reductions in antibiotic use and isolation days.

When culture/reflex required: When organism isolation is needed for antimicrobial susceptibility testing or public health subtyping (e.g., Salmonella), reflex culture or parallel enrichment culture should be performed because multiplex NAATs do not provide isolates.

Systematic reviews and studies recommend parallel culture when isolates are needed (Freeman et al., Tilmanne et al., others).

Low-yield / not routinely indicated scenarios

Not routinely covered / low utility when ANY of the following are met

Asymptomatic screening or low pretest probability: Testing in individuals with low pretest probability or asymptomatic screening given high carriage rates and detection in controls may yield results of uncertain clinical significance.

High positivity in cases and controls and carriage rates complicate interpretation (Tilmanne et al., Meyer et al.).

When results will not change management: Testing that is unlikely to alter clinical management (no anticipated change in antibiotic therapy, isolation, or public health action) is low-yield and not routinely indicated.

Retrospective reviews found low clinical yield with few patients receiving therapy based on results (Clark et al.).

Medically necessary clinical indications

Covered when testing is indicated according to guideline-driven clinical circumstances

Indications per IDSA/ACG/ASM: Testing is indicated for patients with moderate-to-severe, bloody, febrile, dysenteric, nosocomial, or persistent diarrhea; immunocompromised patients; travelers with prolonged diarrhea or specific epidemiologic exposures; and when identification will affect clinical management (such as guiding antibacterial therapy or isolation). Culture-independent multiplex tests are recommended when available for bacterial pathogen detection and may be considered for parasites if diarrhea >7 days. Viral targets are generally of limited impact except in immunocompromised hosts.

Guideline-based indications summarized from IDSA and ACG guidance.

Not routinely indicated

Situations where testing is generally not indicated

Not routinely indicated: No laboratory testing is typically indicated for noninflammatory diarrhea and acute gastroenteritis of limited duration; multiplex viral targets usually have limited clinical impact except in immunocompromised patients.

Per IDSA guidance.

Multiplex PCR panel testing for gastrointestinal pathogens for indications other than those explicitly specified in this policy is considered unproven and not medically necessary.

Culture-independent multiplex molecular tests should not replace culture as the sole diagnostic approach when isolation of an organism is required for antimicrobial susceptibility testing or public health subtyping. Studies comparing PCR-based panels to enrichment and standard cultures show that culture can be more sensitive for some pathogens (for example, Salmonella) and provides isolates needed for confirmatory testing and surveillance; when PCR is used, parallel or reflex culture/enrichment should be performed as indicated.

Culture-independent molecular assays detect nucleic acid from both viable and nonviable organisms and therefore should not be used as tests-of-cure. Clinical interpretation must account for persistence of detectable DNA/RNA after clinical resolution.

Multiplex PCR panel testing for gastrointestinal pathogens that include more than 11 targets is considered unproven and not medically necessary and may be denied.

Broad, unrestricted use of multiplex gastrointestinal panels without applied clinical criteria or in low pretest-probability settings is discouraged. Evidence indicates these assays identify more pathogens but also detect findings of uncertain clinical significance and false positives; limiting testing to patients who meet guideline-driven indications improves yield and reduces unnecessary testing.

Routine laboratory testing is typically not indicated for noninflammatory, self-limited acute diarrhea. Per guideline-based recommendations, testing is generally reserved for moderate-to-severe, bloody, febrile, nosocomial, persistent, or immunocompromised presentations where results would affect management.

Coding and Test Platforms

Applicable CPT CodesCPT

87505	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
87506	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87507	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.

Covered/Discussed test platforms (no billing codes listed in this excerpt)mixed

No codes listed

FDA product codes / example cleared panelsmixed

PCH/PCI (product codes)	FDA 510(k) product codes referenced for searching clearance (informational)
xTAG Gastrointestinal Pathogen Panel	Example commercial multiplex PCR panel with FDA 510(k) clearance (informational).
FilmArray Panels	Example commercial multiplex PCR panel with FDA 510(k) clearance (informational).
Verigene panels	Example commercial multiplex PCR panel with FDA 510(k) clearance (informational).
BioCode Gastrointestinal Pathogen Panels	Example commercial multiplex PCR panel with FDA 510(k) clearance (informational).

Provider Actions, Prior Authorization, and Documentation

Note

Jurisdictional Application

This Medical Policy applies to the state of Ohio. Any requests for services that are stated as unproven or services for which there is a coverage or quantity limit will be evaluated for medical necessity using Ohio Administrative Code 5160-101.

Applies only to Ohio — verify OAC 5160-101 for state-specific requirements.

Prior Authorization

Prior Authorization Recommended

Prior authorization is recommended when testing falls outside IDSA 2017 testing criteria (for example, testing without fever, abdominal pain, bloody stool, or immunocompromising condition in adults) or when panels exceed supported targets. Providers should verify benefit plan requirements and obtain prior authorization where plan rules or state/contractual requirements mandate it.

Prior authorization recommended for testing outside IDSA criteria
Consider prior authorization when ordering multiplex panels > 11 targets (87507)

Background and Evidence Summary

Infectious gastroenteritis is caused by bacteria, viruses, protozoa, and parasites, and clinical presentations range from self-limited watery diarrhea to severe, dysenteric, or systemic illness. Culture-independent multiplex molecular tests have higher sensitivity and faster turnaround than conventional methods and can increase pathogen detection rates, but the clinical importance of additional positive findings is sometimes uncertain. For this reason, molecular testing is most useful when applied to patients with clinical features (for example, fever, bloody stools, severe abdominal pain, prolonged duration, or immunocompromise) where identification will guide therapy, infection-control measures, or public-health actions; culture or enrichment methods remain important when isolates are needed.

Key Definitions

Persistent diarrhea definition

DefinitionDiarrhea lasting more than 7 days.

Policy threshold> 7 days is used to guide expanded panel testing (eligible for up to 11-target panels when other criteria met).

ContextRecommended for persons with persistent symptoms, immunocompromised status, or when parasite testing is being considered.

Suspected enteric fever definition

DefinitionSuspected enteric fever refers to typhoid or paratyphoid in an individual with recent travel to an endemic region or exposure to foods prepared by persons with recent endemic exposure.

Clinical actionObtain blood cultures when enteric fever is suspected; culture-independent and culture-dependent testing should be performed when clinically suspected.

Policy Revision History

03/01/2026Medical records documentation updateLatest

Added language clarifying that medical record documentation may be required to assess whether the member meets clinical criteria for coverage and specifying required content (relevant history, physical exam, diagnostic test results), that documentation must be legible, maintained in the patient record, and made available upon request; Supporting sections (Description of Services, Clinical Evidence, References) were also updated.

OpenPayer

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea (for Ohio Only)